BriaCell Therapeutics Announces $8.5 Million Offering Page 1

Priced on the market according to Nasdaq rules

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 12,325,000 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), priced at the market in accordance with Nasdaq rules. Each share of common stock (or pre-funded warrant) is being sold at an offering price of $0.69 per share (including the exercise price of the pre-funded warrant). All shares of common stock and pre-funded warrants in the offering are being offered by the Company. The total gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are expected to be approximately $8.5 million. The offering is expected to close on September 12, 2024, subject to customary closing conditions. The Company is relying on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions with eligible interlisted issuers on a recognized exchange, such as Nasdaq.

The Company intends to use the net proceeds from the offering for working capital needs, general corporate purposes and to further corporate objectives.

ThinkEquity is acting as sole placement agent for the offering.

The securities described above are being offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. The offering is being made only by means of a written prospectus. A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and may be accessed free of charge on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from the offices of ThinkEquity at 17 State Street, 41^st Floor, New York, New York 10004.